GUSELKUMAB PROVIDES SUSTAINED IMPROVEMENTS IN WORK PRODUCTIVITY AND DAILY ACTIVITY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH 2 YEARS OF DISCOVER-2

被引：0
|
作者：
Curtis, J. [1 ]
Mcinnes, I. [2 ]
Rahman, P. [3 ]
Gladman, D. D. [4 ,5 ]
Yang, F. [6 ]
Peterson, S. [6 ]
Kollmeier, A. [7 ]
Shiff, N. [6 ,8 ]
Han, C. [9 ]
Shawi, M. [10 ]
Tillett, W. [11 ]
Mease, P. J. [12 ,13 ]
机构：
[1] Univ Alabama Birmingham, Dept Med Immunol & Rheumatol, Birmingham, AL USA
[2] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland
[3] Mem Univ Newfoundland, Craig L Dobbin Genet Res Ctr, St John, NF, Canada
[4] Toronto Western Hosp, Schroeder Atrhiritis Inst, Dept Med, Ctr Prognosis Studies Rheumat Dis, Toronto, ON, Canada
[5] Krebmil, Res Inst, Toronto, ON, Canada
[6] Janssen Global Serv LLC, Immunol, Horsham, PA USA
[7] Janssen Res & Dev LLC, Immunol, San Diego, CA USA
[8] Univ Saskatchewan, Dept Community Hlth & Epidemiol, Coll Med, Saskatoon, SK, Canada
[9] Janssen Res & Dev LLC, Immunol, Spring House, PA USA
[10] Janssen Pharmaceut Companies Johnson Johnson, Immunol Global Med Affairs, Horsham, PA USA
[11] Royal Natl Hosp Rheumat Dis, Dept Pharm Pharmacol, Ctr Therapeut Innovat, Bath, Avon, England
[12] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA
[13] Univ Washington, Dept Rheumatol Res, Sch Med, Seattle, WA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.1366
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0888
引用
收藏
页码：1568 / 1569
页数：2
相关论文
共 50 条
  • [21] GUSELKUMAB IMPROVED WORK PRODUCTIVITY AND DAILY ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 3 TRIAL
    Curtis, J.
    Mcinnes, I.
    Rahman, P.
    Tillett, W.
    Mease, P. J.
    Kollmeier, A.
    Hsia, E. C.
    Zhou, B.
    Agarwal, P.
    Peterson, S.
    Han, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1671 - 1671
  • [22] Guselkumab Improved Work Productivity and Daily Activity in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial
    Curtis, Jeffrey R.
    McInnes, Iain
    Rahman, Proton
    Tillett, William
    Mease, Philip
    Kollmeier, Alexa
    Hsia, Elizabeth
    Zhou, Bei
    Agarwal, Prasheen
    Peterson, Steven
    Han, Chenglong
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [23] Efficacy of guselkumab using composite endpoints in patients with active psoriatic arthritis: Domain-specific efficacy from DISCOVER-1 and DISCOVER-2 phase 3 trials
    Coates, Laura C.
    Ritchlin, Christopher T.
    Gossec, Laure
    Helliwell, Philip S.
    Rahman, Proton
    Kollmeier, Alexa P.
    Karyekar, Chetan
    Sheng, Shihong
    Agarwal, Prasheen
    Mease, Philip J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB127 - AB127
  • [24] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN WORK PRODUCTIVITY AND HEALTH RELATED QUALITY OF LIFE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 2-YEAR RESULTS FROM FUTURE 1 AND FUTURE 2
    Strand, V.
    FitzGerald, O.
    Coates, L. C.
    Walsh, J. A.
    Canete, J. D.
    Bhosekar, V.
    Pricop, L.
    Gandhi, K.
    Jugl, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 688 - 688
  • [25] Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
    Mease, Philip J.
    Rahman, Proton
    Gottlieb, Alice B.
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Xu, Xie L.
    Sheng, Shihong
    Agarwal, Prasheen
    Zhou, Bei
    Zhuang, Yanli
    van der Heijde, Desiree
    McInnes, Iain B.
    LANCET, 2020, 395 (10230): : 1126 - 1136
  • [26] Guselkumab Induces Sustained Reduction in Acute Phase Proteins and Th17 Effector Cytokines in Active Psoriatic Arthritis in Two Phase-3 Clinical Trials (DISCOVER-1 and DISCOVER-2)
    Siebert, Stefan
    McInnes, Iain
    Loza, Matthew J.
    Ma, Keying
    Leander, Karen
    Lakshminarayanan, Vani
    Franks, Carol
    Cooper, Philip
    Sweet, Kristen
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [27] Efficacy of guselkumab (GUS) on axial-related endpoints in patients with active psoriatic arthritis (PsA) with imaging-confirmed sacroiliitis: Results through week 52 from DISCOVER-1 and DISCOVER-2
    Gottlieb, Alice B.
    Merola, Joseph F.
    Armstrong, April W.
    Savage, Laura
    Chakravarty, Soumya D.
    Kollmeier, Alexa P.
    Zhou, Bei
    Yang, Ya-Wen
    Sweet, Kristen
    Boehncke, Wolf-Henning
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB39 - AB39
  • [28] GUSELKUMAB INDUCES SUSTAINED REDUCTION IN ACUTE PHASE PROTEINS AND TH17 EFFECTOR CYTOKINES IN ACTIVE PSORIATIC ARTHRITIS IN TWO PHASE-3 CLINICAL TRIALS (DISCOVER-1 AND DISCOVER-2)
    Siebert, S.
    Mcinnes, I.
    Loza, M. J.
    Ma, K.
    Leander, K.
    Lakshminarayanan, V.
    Franks, C.
    Cooper, P.
    Sweet, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 144 - 145
  • [29] Effects of guselkumab on articular components of American College of Rheumatology score and skin responses in patients with active psoriatic arthritis: Results from the phase 3 DISCOVER-2 study
    Gottlieb, Alice B.
    Mease, Philip J.
    Merola, Joseph F.
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Xu, Xie L.
    Agarwal, Prasheen
    van der heijde, Desiree
    McInnes, Iain B.
    Boehncke, Wolf-Henning
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB145 - AB145
  • [30] The Effect of Guselkumab on General Health State in Biologic-Naive Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial
    Curtis, Jeffrey R.
    McInnes, Iain B.
    Rahman, Proton
    Gladman, Dafna D.
    Yang, Feifei
    Peterson, Steven
    Agarwal, Prasheen
    Kollmeier, Alexa P.
    Hsia, Elizabeth C.
    Han, Chenglong
    Shiff, Natalie J.
    Shawi, May
    Tillett, William
    Mease, Philip J.
    ADVANCES IN THERAPY, 2022, 39 (10) : 4632 - 4644
12345